![Discontinuations due to AEs--SINGLE trial: Triumeq vs Atripla at 48 (2% vs 10%), 96 (3% vs 10%), and 144 weeks (4% vs 10%).](/content/dam/global/hcpportal/master/images/homepage/products/triumeq/single_adverse_events_leading_to_discontinuation.jpg)
![Adverse Events ≥5% in SINGLE trial (Triumeq vs Atripla): Triumeq is generally well tolerated vs Atripla through 96 weeks](/content/dam/global/hcpportal/master/images/homepage/products/triumeq/single_adverse_events.png)
Changes in laboratory chemistries
Increases in serum creatinine occurred within the first week of treatment with dolutegravir and remained stable through 96 weeks (Mean change from baseline to 96 weeks: 12.6 μmol/L) 4
- These changes are not considered to be clinically relevant as the glomerular filtration rate remained unchanged
HLA-B*5701 Screening
Review the requirements for HLA-B*5701 screening and reducing the risk of abacavir-related hypersensitivity reactions.
For further information, please see the Summary of Product Characteristics.
*In studies supporting TRIUMEQ, DTG 50 mg + ABC 600 mg/ 3TC 300 mg were used. Bioequivalence has been demonstrated. 2
In some markets, Atripla® is not licensed for initial use in treatment-naive patients.
Atripla is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC.
DTG=dolutegravir.
ABC=abacavir.
3TC=lamivudine.
EFV=efavirenz.
TDF=tenofovir.
FTC=emtricitabine.
References:
- Walmsley S, Antela A, Clumeck N, et al; for the SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807-1818.
- Walmsley S, Berenguer J, Khuong-Josses M, et al. Dolutegravir regimen statistically superior to efavirenz/tenofovir/emtricitabine: 96-week results from the SINGLE study (ING114467). Poster presented at: 21st Conference on Retroviruses and Opportunistic Infections; March 3-6, 2014; Boston, MA. Poster 543.
- Pappa K, Baumgarten A, Felizarta F, et al. Once-daily dolutegravir + abacavir/lamivudine is superior to efavirenz/tenofovir/emtricitabine in treatment-naïve HIV subjects: 144-week results SINGLE (ING114467). Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 5-9, 2014; Washington, DC, USA.
- TRIUMEQ Summary of Product Characteristics.
TRIUMEQ, TIVICAY, ZIAGEN, EPIVIR, KIVEXA, EPZICOM, TRIZIVIR, COMBIVIR
son marcas registradas del grupo de compañías ViiV Healthcare